Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine

Vaccine

Volumn 33, Issue 29, 2015, Pages 3422-3428

  Goss, Mary Ann ^a   Lievano, Fabio ^a   Buchanan, Karyn M ^a   Seminack, Margaret M ^a   Cunningham, Michael L ^b   Dana, Adrian ^a,c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c GENENTECH INC   (United States)

Author keywords

Childbirth; HPV; Pregnancy; Registry

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CANADA; CONGENITAL MALFORMATION; DRUG SAFETY; FETUS DEATH; FRANCE; HUMAN; LIVE BIRTH; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; NEWBORN; NEWBORN DEATH; OUTCOME ASSESSMENT; POSTMARKETING SURVEILLANCE; PREGNANCY; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SPONTANEOUS ABORTION; TWIN PREGNANCY; UNITED STATES; ABORTION, SPONTANEOUS; ADOLESCENT; ADULT; ADVERSE EFFECTS; CHILD; CONGENITAL ABNORMALITIES; FEMALE; PROCEDURES; VACCINATION; YOUNG ADULT;

ABORTION, SPONTANEOUS; ADOLESCENT; ADULT; CANADA; CHILD; CONGENITAL ABNORMALITIES; FEMALE; FRANCE; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY OUTCOME; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; UNITED STATES; VACCINATION; YOUNG ADULT;

EID: 84931572539     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.04.014     Document Type: Article

References (29)

1. Walboomers J.M.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1):12-19.
2. de Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11(11):1048-1056.
3. Srodon M., Stoler M.H., Baber G.B., Kurman R.J. The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am J Surg Pathol 2006, 30(12):1513-1518.
4. de Sanjose S., Alemany L., Ordi J., Tous S., Alejo M., Bigby S.M., et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer 2013, 49(16):3450-3461.
5. Hatch K.D. A3. Vaginal intraepithelial neoplasia (VAIN). Int J Gynecol Obstet 2006, 94(Suppl. 1):S40-S43.
6. Palefsky J.M. Anal squamous intraepithelial lesions: relation to HIV and human papillomavirus infection. JAIDS 1999, 21(Suppl. 1):S42-S48.
7. Picconi M.A., Eiján A.M., Distéfano A.L., Pueyo S., Alonio L.V., Gorostidi S., et al. Human papillomavirus (HPV) DNA in penile carcinomas in Argentina: analysis of primary tumors and lymph nodes. J Med Virol 2000, 61:59-64.
8. Chaturvedi A.K. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health 2010, 46(Suppl. 4):S20-S26.
9. Kjaer S.K., Tran T.N., Sparen P., Tryggvadottir L., Munk C., Dasbach E., et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis 2007, 196(10):1447-1454.
10. Garland S.M., Steben M., Sings H.L., James M., Lu S., Railkar R., et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009, 199(6):805-814.
11. Dana A., Buchanan K.M., Goss M.A., Seminack M., Shields K., Korn S., et al. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol 2009, 114(6):1170-1178.
12. Lehman H.P., Benson J.O., Beninger P.R., Anderson C.A., Blumenthal S.J., Sharrar R.G. A five-year evaluation of reports of overdose with indinavir sulfate. Pharmacoepidemiol Drug Saf 2003, 12(6):449-457.
13. Centers for Disease Control and Prevention Metropolitan Atlanta Congenital Defects Program. Surveillance procedure manual and guide to computerized anomaly record 1998, CDC, Atlanta, GA.
14. Centers for Disease Control and Prevention Birth defects and genetic diseases branch 6-digit code for reportable congenital anomalies, Atlanta, GA, version 08/07. MMWR: Morb Mortal Wkl Rep 2009.
15. March of Dimes. Available at [accessed 31.03.15]. http://www.marchofdimes.org/Peristats/calculations.aspx?reg=%26top=%26id=24.
16. Correa A., Cragan J.D., Kucik J.E., Alverson C., Gilboa S., Balakrishnan R., et al. Reporting birth defects surveillance data, 1968-2003. Birth Defects Res Part A Clin Mol Teratol 2007, 79(2):65-186.
17. MacDorman M.F., Kirmeyer S. Fetal and perinatal mortality, United States, 2005. Natl Vital Stat Rep 2009, 57(8):1-19.
18. Ventura S.J., Abma J.C., Mosher W.D., Henshaw S. Estimated pregnancy rates for the United States, 1990-2000: an update. Natl Vital Stat Rep 2004, 52(23):1-9.
19. Lilienfeld D.E., Stolley P.D. Foundations of epidemiology 1994, Oxford Press, New York. 3rd ed.
20. Merck & Co., Inc. The pregnancy registry for GARDASIL 2012, Merck & Co, Inc., Available at http://www.merckpregnancyregistries.com/gardasil.html [accessed November 2012].
21. Koren G., Bologa M., Long D., Feldman Y., Shear N.H. Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester. Am J Obstet Gynecol 1989, 160(5 Pt 1):1190-1194.
22. Pole M., Einarson A., Pairaudeau N., Einarson T., Koren G. Drug labeling and risk perceptions of teratogenicity: a survey of pregnant Canadian women and their health professionals. J Clin Pharmacol 2000, 40(6):573-577.
23. The 2002 FDA guidance for industry: establishing pregnancy exposure registries 2009, Food and Drug Administration, Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071639.pdf [accessed 08.06.09].
24. Scott J.R. Early pregnancy loss. Danforth's obstetrics and gynecology 1999, 143-153. Lippincott Williams & Wilkins, Philadelphia. J.R. Scott, P.J. DiSaia, C.B. Hammond, W.N. Spellacy (Eds.).
25. Fox R., Pillai M., Porter H., Gill G. The management of late fetal death: a guide to comprehensive care. Br J Obstet Gynaecol 1997, 104(1):4-10.
26. Patel E., Goodnight W., James A., Grotegut C. Temporal trends in maternal medical conditions and stillbirth. AJOG 2014, [online].
27. Weng Y.H., Yang C.Y., Chiu Y.W. Risk assessment of adverse birth outcomes in relation to maternal age. PLOS ONE 2014, 9(10 December (12)):e114843. 10.1371/journal.pone.0114843.
28. Croen L.A., Shaw G.M. Young maternal age and congenital malformations: a population-based study. Am J Public Health 1995, 85(May (5)):710-713.
29. Jerrold S. Levine, M.D., D. Ware Brance, M>D>, and Joyce Rauch, Ph.D. The Antiphospholipid Syndrome. NEJM: Volume 346: 752-63, March 7, 2002, Number 10.